Newsfiscal.ai
Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1
· Published
Article summary
Opus Genetics has finished dosing the second cohort in its BIRD-1 Phase 1/2 clinical trial evaluating OPGx-BEST1 for the treatment of inherited retinal diseases.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…